Atrial natriuretic peptide and arginine-vasopressin secretion in patients with active renal stone disease

被引：5
作者：
Kokot F. [1 ]
Klimek D. [1 ]
Wiȩcek A. [1 ]
Kuczera M. [1 ]
机构：
[1] Department of Nephrology, Silesian University, School of Medicine, Katowicze
来源：
International Urology and Nephrology | 1998年 / 30卷 / 3期
关键词：
Atrial Natriuretic Peptide; Mean Arterial Blood Pressure; Water Immersion; International Urology; Atrial Natriuretic Factor;
D O I：
10.1007/BF02550323
中图分类号：
学科分类号：
摘要：
The pathogenesis of active renal stone disease (ARSD) is still not fully elucidated. In the present study the role of atrial natriuretic peptide (ANP) and argininevasopressin (AVP) as potential pathogenetic factors in ARSD were examined. Thirty patients with ARSD and 21 healthy subjects (HS) were examined both under bed rest (BR) and head-out water immersion (WI) conditions. Serum concentrations of electrolytes (Na, Ca, Mg), ANP and AVP were assessed before (0'), and after 60 and 120 minutes of BR or WI, respectively. Urinary excretions of Na, Ca, Mg, and oxalates were also estimated during BR and WI. Patients with ARSD showed higher basal plasma levels of ANP and a greater response of ANP secretion, but a lower suppression of plasma AVP to WI induced hypervolaemia as compared with the controls. In addition, in patients with ARSD the physiological relationship between plasma AVP concentration and urinary excretion of Ca and Mg (positive correlation), between plasma ANP level and urinary excretion of Ca and Mg (negative correlation), and between plasma ANP and AVP concentration (negative correlation), respectively, were absent. In addition, patients with ARSD showed a positive correlation between plasma ANP and urinary oxalate excretion. From the results obtained in this study we conclude that both AVP and ANP may be involved in the pathogenesis of ARSD.
引用
收藏
页码：357 / 365
页数：8
相关论文
共 28 条
  • [1] Anand-Srivastava, M.B., Cantin, M., Genest, I., Inhibition of pituitary adenylate cyclase by atrial natriuretic factor (1985) Life Sci., 36, p. 1873
  • [2] Anderson, J.V., Donckier, J., Payne, N.N., Beacham, J., Slater, J.D., Bloom, S.R., Atrial natriuretic peptide: Evidence of action as a natriuretic hormone at physiological plasma concentrations in man (1987) Clin. Sci., 72, p. 305
  • [3] Biollaz, J., Nussberger, J., Porchet, M., Brunner-Ferber, F., Otterbein, E.S., Gomez, H., Waeber, B., Brunner, H.R., Four-hour infusions of synthetic atrial natriuretic peptide in normal volunteers (1986) Hypertension, 8 (2 SUPPL.), p. 1196
  • [4] Broadus, A.E., Horst, R.L., Lang, L., Liftledike, E.T., Rasmussen, H., The importance of circulating 1,25 dihydroxyvitamin D in the pathogenesis of hypercalciuria and renal-stone formation in primary hyperparathyroidism (1980) N. Engl. J. Med., 302, p. 421
  • [5] Coe, F.L., Parks, J.H., Asplin, J.R., The pathogenesis and treatment of kidney stones (1992) N. Engl. J. Med., 327, p. 1141
  • [6] Dillingham, M.A., Anderson, R.J., Inhibition of vasopressin action by atrial natriuretic factor (1986) Science, 231, p. 1572
  • [7] Fujio, M., Ohasi, M., Nawata, M., Kato, K., Ibayashi, H., Kangawa, K., Matsuo, H., Alpha-human atrial natriuretic polypeptide reduces the plasma arginine vasopressin concentration in human subjects (1986) Clin. Endocrinol., 25, p. 181
  • [8] Gerbes, A.L., Vollmar, A.M., Degradation and clearance of atrial natriuretic factors (ANF) (1990) Life Sci., 47, p. 1173
  • [9] Greenleaf, J.E., Shvartz, E., Keil, L.C., Hemodilution, vasopressin suppression, and diuresis during water immersion in man (1981) Aviat. Space Environ. Med., 52, p. 329
  • [10] Kiersztejn, M., Kuczera, M., Kokot, F., Verhalten der Prolaktinsekretion und des 25-Hydroxy-cholecalciferolspiegels bei Kranken mit aktiver Nierensteinkrankheit (1988) Z. Urol. Nephrol., 81, p. 431
123